Comparing of Kamada Ltd. (KMDA) and Acorda Therapeutics Inc. (NASDAQ:ACOR) – MS Wkly

Both Kamada Ltd. (NASDAQ:KMDA) and Acorda Therapeutics Inc. (NASDAQ:ACOR) are Biotechnology companies, competing one another. We will compare their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

Table 1 shows the gross revenue, earnings per share and valuation for Kamada Ltd. and Acorda Therapeutics Inc.

Profitability

Table 2 provides us Kamada Ltd. and Acorda Therapeutics Inc.s net margins, return on assets and return on equity.

Analyst Ratings

In next table is given Kamada Ltd. and Acorda Therapeutics Inc.s ratings and recommendations.

On the other hand, Acorda Therapeutics Inc.s potential upside is 161.57% and its average price target is $6.67.

Insider & Institutional Ownership

Roughly 25.39% of Kamada Ltd. shares are held by institutional investors while 0% of Acorda Therapeutics Inc. are owned by institutional investors. About 27.75% of Kamada Ltd.s share are held by insiders. Competitively, 1.5% are Acorda Therapeutics Inc.s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Kamada Ltd. had bullish trend while Acorda Therapeutics Inc. had bearish trend.

Summary

Kamada Ltd. beats on 7 of the 12 factors Acorda Therapeutics Inc.

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The companys respiratory products include Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency (AATD); Bramitob to manage chronic pulmonary infection; and FOSTER for the treatment of asthma. Its immunoglobulin products comprise KamRAB for prophylaxis against rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra, a hepatitis B immunoglobulin; Hepatect CP, a hepatitis B immunoglobulin; and Megalotect, a CMV immunoglobulin. The company also provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of blood plasma. In addition, it offers other products, including Heparin Lock Flush to maintain patency of indwelling IV catheter; Kamacaine 0.5% used as anesthesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; Human Transferrin for diagnostic assays and cell cultures; and coagulation factors comprising Factor VIII and Factor IX. Further, the company develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, graft-versus-host diseases, and transplantations. Kamada Ltd. has strategic partnerships with Baxter International Inc.; Chiesi Farmaceutici; PARI GmbH; and Kedrion S.p.A. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinsons disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinsons disease; SYN120, which is in Phase II clinical trial to treat Parkinsons disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Womens Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the article here:
Comparing of Kamada Ltd. (KMDA) and Acorda Therapeutics Inc. (NASDAQ:ACOR) - MS Wkly